NASDAQ:FLNA

Cassava Sciences Q4 2025 Earnings Results & Report

Cassava Sciences logo
$0.53 +0.05 (+11.15%)
As of 02:47 PM Eastern

Cassava Sciences beat analyst earnings expectations in its Q4 2025 results, released March 12, 2026. The company reported EPS of -$0.26 versus the -$0.30 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
10:30 AM ET

Cassava Sciences EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.30
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Cassava Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Cassava Sciences Q4 2025 Earnings FAQ

Cassava Sciences (NASDAQ:FLNA) reported earnings of -$0.26 per share for Q4 2025, beating the consensus estimate of -$0.30. The report was announced on Thursday, March 12, 2026.

Cassava Sciences Earnings Headlines

Cassava Sciences (NASDAQ:FLNA) Stock Sees Heavy Call Option Buying
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
See More Cassava Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email.

About Cassava Sciences

Cassava Sciences (NASDAQ:FLNA) is a biotechnology company focused on developing treatments and diagnostic tools for Alzheimer’s disease. The company’s Nasdaq ticker is SAVA; FLNA does not correspond to Cassava Sciences.

Its research has included simufilam, an investigational oral drug candidate studied for Alzheimer’s, and SavaDX, a blood-based diagnostic program. These are products under development, not approved treatments or tests.

Founded in 1998 as Pain Therapeutics, the company adopted the Cassava Sciences name in 2018. It is headquartered in Austin, Texas, and has been led by founder and chief executive Remi Barbier.

View Cassava Sciences Profile